Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of icotinib in combination with
radiotherapy for NSCLC patients with brain metastases. The primary endpoint is PFS of
intracranial lesions